Efficacy of angiotensin II receptor blocker versus sacubitril valsartan on Blood pressure and glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes complicated by hypertension

Efficacy of angiotensin II receptor blocker versus sacubitril valsartan on Blood pressure and glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes complicated by hypertension - Efficacy of angiotensin II receptor blocker versus sacubitril valsartan on Blood pressure and glycemic control measured by continuous glucose monitoring in adults with type 2 diabetes complicated by hypertension

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000051350

Enrollment

Registered

2023-06-20

Start date

2023-06-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

angiotensin II receptor blocker Sacubitril Valsaltan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes mellitus patients with hypertension over 20 years of age Patients who have been treated with the maximum dose of angiotensin II receptor blocker Patients with systolic Blood pressure 135mmHg or more Patients with HbA1c 6.5% or more and less than 10.5%

Exclusion criteria

Exclusion criteria: Patients diagnosed with type 1 diabetes Individuals who have a hypersensitivity to Sacubitril valsartan or angiotensin II receptor blockers History of angioedema severe renal dysfunction (eGFR < 30 mL/min/1.73 m2) severe hepatic dysfunction (Child-Pugh classification C) pregnant women, or individuals who may be pregnant other patients who the physician deems unsuitable should avoid using this medication.

Design outcomes

Primary

Measure	Time frame
Change systolic blood pressure from baseline to week 16	—

Secondary

Measure	Time frame
Proportion of Time In Tight Range at Week 16 Others of Glycemic indicator Change albuminuria from baseline to week 16	—

Countries

Japan

Contacts

Public ContactYasutake Shinohara

Tochigi Medical Center Shimotsuga Diabetes and Endocrinology

yasutale@dokkyomed.ac.jp0282-22-2551

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026